Uncategorized
NSF-Funded Test Bed Lets Researchers Program Automated Biomanufacturing Workflows
The U.S. National Science Foundation (NSF) awarded the University of Maryland in College Park $17.3 million to launch a test bed for users from across the U.S. to program automated workflows for experiments in biomanufacturing.
UMD’s Collaborative for the Realization of Autonomous Biomanufacturing (CRAB) Lab is one of 20 Programmable Cloud Laboratory Node sites supported through a $400 million NSF investment. The network’s goal is to create AI-enabled laboratories that test, scale, and demonstrate novel methods and tools for automated science, engineering discoveries, and translation.
“Being selected for this award reflects UMD’s commitment to solving real biomanufacturing challenges,” said William Bentley, PhD, Robert E. Fischell Distinguished Professor, director of the Robert E. Fischell Institute for Biomedical Devices and CRAB Lab principal investigator. “What excites me most about the CRAB Lab is that it’s not just conducting research. It’s contributing to a national resource where researchers across academia, industry, and government will be able to access experiment data and automation capabilities that would otherwise be out of reach.”
Provides datasets for training AI models
Biomanufacturing faces a critical need for real-time data processing. Traditional molecular measurement processes are too slow to train AI models, limiting the potential for experiment optimization and scaling. The CRAB Lab will incorporate an electronic measurement tool, developed at the Fischell Institute in partnership with the National Institute of Standards and Technology (NIST) and the FDA.
The tool allows for high-velocity, high-volume measurements to complement molecular data, providing comprehensive datasets for training AI models. With this information, models will be able to identify new biological vital signs—key combinations of measurements that correlate to product quality, titer and other critical process attributes—to optimize biomanufacturing processes for scale, according to Bentley, who is also appointed in UMD’s Fischell Department of Bioengineering and Institute for Bioscience and Biotechnology Research (IBBR).
The CRAB Lab builds on a long-standing partnership between UMD and NIST through IBBR, which will serve as the physical home for instrumentation, facilities and scientific expertise. The lab plans to integrate UMD’s AI and biosensor technology proficiency with industrial-scale biomanufacturing expertise from Ginkgo Bioworks.
The CRAB Lab is also aligned with the recently initiated Center for Biomeasurement and Biomanufacturing Innovation, a $33 million collaboration between UMD, UMD-Baltimore, and NIST. It is designed to accelerate the translation of new technologies to industry, to “increase the pace and lessen the costs of developing the next generation of biotherapeutics,” noted IBBR director Jonathan Dinman, PhD, a professor of cell biology and molecular genetics at UMD.
The CRAB Lab will initially serve 30 biopharmaceutical companies addressing industry-wide challenges through the Advanced Mammalian Biomanufacturing Innovation Center, an NSF Industry-University Cooperative Research Center.
“AI paired with autonomous labs is how discoveries get made and scaled at the same time,” pointe out Jason Kelly, PhD, co-founder and CEO of Ginkgo Bioworks. “The CRAB Lab gives researchers and manufacturers a shared, real-time feedback loop that could move biomanufacturing innovation from years to months.”
In addition to accelerating research, the CRAB Lab will establish on-site and remote educational programs through a dedicated training hub at The Universities at Shady Grove. These initiatives are intended to develop the workforce required for high-demand jobs in biomanufacturing.
The post NSF-Funded Test Bed Lets Researchers Program Automated Biomanufacturing Workflows appeared first on GEN – Genetic Engineering and Biotechnology News.
Uncategorized
New webinar: Tackling drug discovery challenges in cancer research

Hosted by Drug Discovery World and supported by Sartorius and BioIVT, this webinar will explore the opportunities and challenges that exist within cancer research drug discovery and development.
You will hear from Dr Sudha Rao, Chief Scientific Officer of Kazia Therapeutics, Karol Budzik, PhD, Business Development Associate at Vyriad Therapeutics and Lars van der Veen, Chief Scientific Officer at iOnctura.
Presentations will cover how cancer treatments have shifted towards reprogramming the biology driving tumour growth, immune escape and treatment resistance, the trajectory that in vivo CAR-T treatments are taking, and how challenging tumours burdened by stroma and immune-mediated resistance can be tackled.
Q&A with the speakers follows the presentations.
The post New webinar: Tackling drug discovery challenges in cancer research appeared first on Drug Discovery World (DDW).
Uncategorized
Psilocybin proves promising in neuropathic pain mouse study
Amid the rise of psychedelics in the mental health space, researchers have begun to explore psilocybin as a treatment for chemotherapy-induced peripheral neuropathy.
Uncategorized
New Spectrometry Technique Could Aid Formulation Development
New Spectrometry Technique Could Aid Formulation Development
A new technique combining two forms of spectrometry could help biopharmaceutical companies improve their choice of formulation buffer for antibody manufacturing by revealing how molecular forms and three-dimensional shapes of complex biologics respond to their environment. That’s the view of Christian Bleiholder, PhD, a professor at Florida State University who helped develop the technique.
According to Bleiholder, what happens structurally when a complex biological molecule, such as an antibody or viral spike protein, binds to its target is currently poorly understood.
“This is where [this approach] can help with the bioprocessing and formulation,” he says, as structural changes “can affect the lifespan [of the product] and lead to issues, such as aggregation.”
Because antibodies are complex, existing techniques tend to be powerful at different levels of complexity, he explains. Mass spectrometry is particularly powerful for distinguishing molecular composition, while structural approaches such as X-ray crystallography and cryo-electron microscopy can provide high-resolution structural information.
The challenge is understanding the link between these things within a heterogeneous sample, he says.
To overcome this, Bleiholder and his team worked with Bruker Daltonics to develop Tandem-Trapped Ion Mobility Spectrometry (Tandem-TIMS). This combines tandem ion mobility spectrometry with tandem mass spectrometry to disentangle three overlapping layers of molecular complexity: molecular form, three-dimensional shape, and binding or assembly state, he says.
He explains that, if the proteins have different structures, they can be characterized with tandem ion mobility spectrometry, and then mass spectrometry can be used to look at their molecular forms and binding states.
Going forward, Bleiholder hopes the technique can be used for formulation development but also earlier, during drug discovery of new products, such as multi-specific antibodies, to determine which molecular states are important and how those change when a biologic engages its target. He also plans to look at automating the technique.
Bleiholder spoke about using Tandem-TIMS at the Bioprocessing Summit in Boston earlier this year.
The post New Spectrometry Technique Could Aid Formulation Development appeared first on GEN – Genetic Engineering and Biotechnology News.
-
Uncategorized8 months agoNovartis buys Synnovation’s PI3Kα inhibitors for $3 billion
-
Endpoints News8 months ago
Novartis to pay $2B upfront to take next-gen PI3Kα inhibitor from Synnovation
-
Uncategorized7 months agoOptical Pooled CRISPR Screen Reveals Regulators of NF-κB Dynamics in Human Cells
-
Uncategorized6 months ago
Relay’s PI3Kα inhibitor clears efficacy bar in Phase 2 vascular anomalies study
-
Uncategorized6 months ago
Hybrid solid−liquid optics enable scalable, high-resolution light-sheet microscopy across diverse immersion media
-
Fierce Biotech8 months ago
Scientists turn pig semen extract into eye drops that kill cancer in mice
-
Nature Biotechnology8 months ago
Sustained nitric oxide production by engineered E. coli remodels the tumor microenvironment and potentiates immunotherapy
-
Nature Biotechnology8 months ago
Mapping cis-regulatory mutations at scale in sorghum enables modulation of gene expression
Scan to Read